GlassScriptPhysician profile
Michael George Ward
NPI 1710953070
$11,645.18
in general payments reported to CMS, 2019-2025
35 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 95% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $1,382 · 2021: $1,735 · 2022: $1,516 · 2023: $1,232 · 2024: $2,129 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,718 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,717.60 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,136.43 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,957.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,541.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $746.68 | 2022-2025 | |
| Glaxosmithkline, LLC. | $708.53 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $519.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.55 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $499.24 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $391.33 | 2019-2023 | Xarelto |
| Corcept Therapeutics | $386.28 | 2022-2025 | Korlym |
| Radius Health, INC. | $344.19 | 2024-2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $290.30 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $207.01 | 2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $179.15 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $173.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $141.78 | 2023-2025 | Linzess, Viberzi |
| Abbott Laboratories | $110.71 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Currax Pharmaceuticals LLC | $70.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.47 | 2025 | Zoryve |
| Dexcom, INC. | $62.36 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.23 | 2023-2024 | Xifaxan |
| Medtronic, INC. | $53.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $50.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $39.21 | 2022 | |
| Depuy Synthes Sales INC. | $33.34 | 2022-2024 | Monovisc |
| Phadia US INC. | $32.67 | 2022-2025 | Immunocap |
| Embecta Corp. | $23.93 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $23.14 | 2025 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $21.74 | 2024 | Thinprep 2000 Processor |
| Agile Therapeutics, INC. | $17.92 | 2021 | |
| Genentech USA, INC. | $16.36 | 2021 | |
| Amgen INC. | $15.66 | 2025 | Repatha |
| Azurity Pharmaceuticals, INC. | $14.29 | 2023 | Edarbi |
| Amarin Pharma, INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.